10:01 AM EST - DiagnoCure Inc : announced positive initial results of a multi-center clinical study of 241 stage II colon cancer patients, a population categorized as low risk by traditional methods yet with an average recurrence rate of 20%. DiagnoCure Inc
shares T.CUR are trading down $0.03 at $0.97.
